HomeIndustriesHealthcareNKGen Biotech (NKGN) CEO & CFO On "Natural Killer" Cell Therapeutics

NKGen Biotech (NKGN) CEO & CFO On "Natural Killer" Cell Therapeutics

NKGen Biotech (NKGN) is a clinical stage biotechnology company that went public via SPAC merger today. CEO Paul Y. Song and CFO James Graf join Nicole Petallides to discuss NKGN. NKGEN is focused on development and commercialization of natural killer (“NK”) cell therapeutics for neurodegenerative and oncological diseases. They talk about the role of “Natural Killer” cells in treating neurodegenerative diseases and cancer. They go over how NK cell therapeutics have the potential to be a possible treatment for Alzheimer’s and Parkinson’s disease. They also outline therapeutics in development at NKGen Biotech. Tune in to find out more about the stock market today.

The Watch List

02 Oct 2023

SHARE

ON AIR
education
4:30 am
Inside the Mind of a Trader
replay
education
12:00 am
Your First Trade
REPLAY
education
12:30 am
Your First Trade
REPLAY
1:00 am
The Wrap
REPLAY
2:00 am
Fast Market
REPLAY
3:00 am
Next Gen Investing
REPLAY
4:00 am
Market Overtime
REPLAY
ON AIR
education
4:30 am
Inside the Mind of a Trader
REPLAY
education
5:00 am
Inside the Mind of a Trader
REPLAY
education
5:30 am
Inside the Mind of a Trader
REPLAY
6:00 am
Market Overtime
REPLAY
7:00 am
Morning Movers
8:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
3:30 pm
Market Overtime
REPLAY
4:00 pm
Fast Market
REPLAY
5:00 pm
Next Gen Investing
REPLAY
6:00 pm
The Wrap
REPLAY
7:00 pm
Market Overtime
REPLAY
7:30 pm
Market Overtime
REPLAY
8:00 pm
The Wrap
REPLAY
9:00 pm
Market Overtime
REPLAY
10:00 pm
Fast Market
REPLAY
11:00 pm
Next Gen Investing
REPLAY

Schwab Network's Newsletters

Daily insights for every investor